Company Focus
IQVIA INC.
Latest IQVIA INC. News
Pharmaceutical
Rising use of innovative medicines and shifting spending patterns are reshaping the global pharmaceutical landscape, according to a new report from US data analytics group IQVIA. 27 June 2025
Related News
Insights
Company Spotlight
A data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases.
Latest News & Features of interest to IQVIA INC.
Pharmaceutical
US biotech major Amgen, a late comer to the growing obesity treatment space, released new data showing that its MariTide reduced weight by 20%. In deal-making news last week, US drugmaker Amarin struck a deal with Italy’s Recordati for the marketing of its cardiovascular drug Vazkepa in 59 countries, mostly Europe. Also, USA-based Vor Bio signed an exclusive agreement to acquire to RemeGen’s myasthenia drug telitacicept. Also of note, the US Centers for Disease Control and Prevention CDC) new advisory committee, the ACIP, met last week to review a number of vaccines. 29 June 2025
Biotechnology
North Carolina, USA-based biotech BioCryst Pharmaceuticals on Friday announced it has signed a definitive agreement to sell its European Orladeyo (berotralstat) business to Italy’s Neopharmed Gentili for up to $264 million. 28 June 2025
article
Swedish Orphan Biovitrum, the Nordic biotech also known as Sobi on Frida,y announced that the US Food and Drug Administration (FDA) approved Gamifant (emapalumab-lzsg) for a new indication, edging the company’s shares up 2.4% to 284.60 kronor. 28 June 2025
Biotechnology
Alphabet-founded biotech Calico Life Sciences has struck an exclusive licensing agreement with Chinese drugmaker Mabwell for investigational therapies aimed at interleukin-11 (IL-11), including a Phase I-stage monoclonal antibody targeting age-related conditions. 27 June 2025
Pharmaceutical
German drugmaker Bayer has renewed its partnership with China’s Tsinghua University for another three years, reinforcing its strategy to develop treatments aligned with China’s growing role in global biopharma R&D. 27 June 2025
Biotechnology
US biotech major Biogen today announced new data that reinforce the clinical impact of nusinersen across a broad spectrum of individuals affected by spinal muscular atrophy (SMA). 27 June 2025
Pharmaceutical
Despite calls for the meeting to be delayed, Wednesday’s meeting of the Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices (ACIP) went ahead. 27 June 2025
Biotechnology
In a significant showcase for investors, BeOne Medicines announced major advancements to its industry-leading oncology pipeline during an investor R&D Day. 27 June 2025
Biotechnology
Italian drugmaker Philogen has announced its decision to voluntarily withdraw the application for marketing authorization to the European Medicines Agency (EMA) for Nidlegy(daromun), a biological investigational medicinal product which is intended to be used for the neoadjuvant treatment of adult patients with locally advanced fully resectable melanoma. 27 June 2025
Pharmaceutical
Japanese drugmaker Chugai Pharmaceutical today revealed that it has filed a regulatory application with the Ministry of Health, Labor and Welfare (MHLW) for an additional indication of its anti-cancer agent/ALK inhibitor Alecensa (alectinib) for ALK fusion/rearrangement gene-positive unresectable advanced or recurrent solid tumors, including pediatric patients. 27 June 2025
Latest In Brief for IQVIA INC.
Biosimilars
The European Medicines Agency’s human medicines committee (CHMP) adopted positive opinions for six biosimilar medicines at its June meeting. 20 June 2025
Latest Relevant Ones To Watch News
Notable research news last week included Sarepta Therapeutics reporting another death associated with a trial of its Duchenne muscular dystrophy drug Elevidys. On the M&A front, US pharma major Eli Lilly last Tuesday announced it is to acquire Verve Therapeutics for up to $1.3 billion, along with its VERVE-102. Regulatory news saw the US Food and Drug Administration (FDA) announce a new voucher program aimed at enhancing the health interests of Americans. The FDA also approved Incyte’s Monjuvi for relapsed or refractory follicular lymphoma (LF). 22 June 2025
17 June 2025
16 June 2025
12 June 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze